Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 23, 2022 - Issue 7
Submit an article Journal homepage
1,446
Views
5
CrossRef citations to date
0
Altmetric
Editorial

What are the main considerations when prescribing pharmacotherapy for Parkinson’s disease?

Thomas MüllerDepartment of Neurology, St. Joseph Hospital Berlin-Weißensee, Berlin, GermanyCorrespondence[email protected] [email protected]
ORCID Iconhttps://orcid.org/0000-0002-6799-0753View further author information
ORCID Icon
Pages 745-750 | Received 26 Jul 2021, Accepted 18 Feb 2022, Published online: 25 Feb 2022

Citations (5)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (4)

Thomas Müller. (2023) The role of istradefylline in the Parkinson’s disease armamentarium. Expert Opinion on Pharmacotherapy 24:7, pages 863-871.
Read now
Thomas Müller, Peter Riederer & Wilfried Kuhn. (2023) Aminoadamantanes: from treatment of Parkinson’s and Alzheimer’s disease to symptom amelioration of long COVID-19 syndrome?. Expert Review of Clinical Pharmacology 16:2, pages 101-107.
Read now
Alaina N Elliott-Wherry, Jennifer E Lee, Amy M Pearlman & Terry L Wahls. (2022) The Wahls Behavior Change Model for Complex Chronic Diseases: A Clinician’s Guide. Degenerative Neurological and Neuromuscular Disease 12, pages 111-125.
Read now
Thomas Müller. (2022) Perspective: cell death mechanisms and early diagnosis as precondition for disease modification in Parkinson’s disease: are we on the right track?. Expert Review of Molecular Diagnostics 22:4, pages 403-409.
Read now

Articles from other publishers (1)

Thomas Müller. (2022) Perspective: Is a Closer Interaction between Experimental and Clinical Research Paradigms in Chronic Neurodegeneration, Such as Parkinson’s Disease, Necessary Again?. Cells 12:1, pages 157.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.